Filing and period
Entity and period mismatch: The supplied filing is Helius Medical Technologies, Inc.’s Form 10-K for the fiscal year ended March 31, 2016, not a filing for Solana Co or “2015 Q4.” Financial figures below are in U.S. dollars unless stated otherwise.
Business context
Helius is a pre-revenue medical technology company developing the PoNS device, a non-invasive tongue-based neuromodulation device intended for use with rehabilitation. Its initial target is balance disorder associated with mild-to-moderate traumatic brain injury (TBI); multiple sclerosis (MS) is a planned additional indication. The device had not received FDA clearance, and the company had no commercial product sales during either year presented.
Financial performance and liquidity
| Metric | FY ended Mar. 31, 2016 | FY ended Mar. 31, 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $3.646 million | $4.500 million |
| General and administrative | $5.672 million | $5.308 million |
| Total operating expenses | $9.317 million | $9.808 million |
| Net loss | $6.882 million | $9.838 million |
| Basic loss per share | $0.10 | $0.17 |
| Cash used in operating activities | $7.937 million | $6.321 million |
| Cash and cash equivalents at year-end | $2.644 million | $0.419 million |
Operating margins are not meaningful because the company had no revenue. The year-over-year reduction in net loss included a $2.083 million non-cash gain from the change in fair value of derivative liabilities; results also included $0.268 million of gain on debt extinguishment. These items make the reported loss an incomplete measure of operating performance.
At March 31, 2016, total assets were $4.041 million, total liabilities $4.057 million, and stockholders’ deficit $16,192. Current assets were $4.041 million and current liabilities $2.331 million, yielding reported working capital of $1.410 million. Derivative liabilities were $1.726 million; the filing does not present a clear conventional borrowing balance outstanding at year-end. Financing activities provided $9.691 million during FY2016, primarily through private placements and the A&B financing.
Changes, outlook and key risks
- R&D expense declined by $0.854 million, primarily because U.S. Army research reimbursements of $0.597 million were credited against expenses. General and administrative expense increased by $0.363 million.
- The TBI registration trial timeline slipped: management expected completion in the first quarter of calendar 2017, versus an earlier target of the first quarter of 2016, citing slower-than-expected enrollment. The company’s expected commercial-device release shifted to Q4 2016; FDA filing was anticipated in the first half of 2017, with clearance targeted for Q3 2017 if FDA review proceeded as expected. These are projections, not guarantees.
- The company reported substantial doubt about its ability to continue as a going concern and said existing resources were insufficient to fund operations beyond Q4 2016 without additional capital. Subsequent to year-end, it reported an offering with total gross proceeds of CAD $10.305 million, including the over-allotment, and CAD $1.826 million from warrant exercises. Those later proceeds do not eliminate the disclosed financing and execution risks.
- Under a cost-sharing contract, the U.S. Army was to reimburse approximately 62% of initially budgeted trial costs, up to $2.996 million; $1.458 million had been received by year-end. The agreement was due to expire December 31, 2016, and the Army had no obligation to buy the device.
- Accounting and reporting are notable concerns: the company restated interim financial statements for warrant accounting and had previously restated statements related to non-employee stock-option valuation. Management said disclosure controls and internal control over financial reporting were ineffective at March 31, 2016, citing insufficient technical accounting expertise; remediation was ongoing.
- Other material risks include regulatory or clinical failure, additional trial delays and capital needs, uncertain reimbursement and market adoption, dependence on third-party manufacturing, and patent-related disputes. Wicab had threatened proceedings challenging two licensed patents; settlement discussions were ongoing. A separate consulting-related lawsuit was settled for €57,000 and dismissed without prejudice. The A&B agreement provides for a $2.0 million penalty if specified FDA-clearance or U.S. Government availability conditions are not met by December 31, 2017.
Important facts for investors to verify
- Confirm the intended issuer and reporting period: the source is Helius Medical Technologies’ FY2016 10-K, not a Solana Co 2015 Q4 filing.
- Review the audited financial statements and restatement disclosures, particularly derivative-warrant valuation and the non-cash fair-value gain affecting FY2016 results.
- Reconcile operating cash use: the audited cash-flow statement reports $7.937 million, while another risk-factor passage cites $7.817 million.
- Assess the company’s post-year-end financing, cash runway, and ability to fund trial completion and commercialization.
- Track TBI trial results and timing, FDA/foreign clearances, Army contract extension and reimbursements, and any change in the patent dispute or A&B penalty exposure.